Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis
Launched by PRINCE OF SONGKLA UNIVERSITY · Oct 9, 2019
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
Efficacy and RCT compare roflumilast vs placebo for 6 months in frequent infectious exacerbation in non-cystic bronchiectasis in Thailand
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • symptomatic Bronchiectasis
- • history at least 2 exacerbation last year
- Exclusion Criteria:
- • comorbidity with chronic obstructive pulmonary disease
About Prince Of Songkla University
Prince of Songkla University (PSU) is a prestigious academic institution located in Thailand, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, PSU leverages its extensive resources and expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among multidisciplinary teams of researchers, healthcare professionals, and students, ensuring rigorous study designs and adherence to ethical standards. PSU's dedication to improving public health outcomes is reflected in its focus on translating research findings into practical applications that benefit local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Songkhla, , Thailand
Patients applied
Trial Officials
Kanung Saejiam, MS
Study Director
Prince of Songkla University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials